Adi Diab

Adi Diab

UNVERIFIED PROFILE

Are you Adi Diab?   Register this Author

Register author
Adi Diab

Adi Diab

Publications by authors named "Adi Diab"

Are you Adi Diab?   Register this Author

57Publications

2463Reads

13Profile Views

Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade.

Int J Dermatol 2019 Sep 20;58(9):1045-1052. Epub 2017 Nov 20.

Department of Pathology, Section of Dermatopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijd.13833DOI Listing
September 2019

IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy.

Cancer Immunol Res 2019 Jun 17;7(6):860-865. Epub 2019 Apr 17.

Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-18-0682DOI Listing
June 2019

Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma.

Cancer Immunol Immunother 2019 Apr 21;68(4):553-561. Epub 2019 Jan 21.

Department of Gastroenterology, Hepatology and Nutrition, The University of Texas, MD Anderson Cancer Center, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00262-019-02303-1
Publisher Site
http://dx.doi.org/10.1007/s00262-019-02303-1DOI Listing
April 2019

Characteristics and Prognostic Factors for Patients With HER2-overexpressing Breast Cancer and Brain Metastases in the Era of HER2-targeted Therapy: An Argument for Earlier Detection.

Clin Breast Cancer 2018 10 21;18(5):353-361. Epub 2017 Dec 21.

Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2017.12.009DOI Listing
October 2018

Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor.

J Cutan Pathol 2018 Oct 3;45(10):786-790. Epub 2018 Aug 3.

Department of Pathology, Section of Dermatopathology, MD Anderson Cancer Center, The University of Texas, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cup.13319DOI Listing
October 2018

Immune-Related Thyroiditis with Immune Checkpoint Inhibitors.

Thyroid 2018 10;28(10):1243-1251

1 Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine; The University of Texas MD Anderson Cancer Center , Houston, Texas.

View Article

Download full-text PDF

Source
https://www.liebertpub.com/doi/10.1089/thy.2018.0116
Publisher Site
http://dx.doi.org/10.1089/thy.2018.0116DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157359PMC
October 2018

Metastatic Melanoma of the Optic Nerve Sheath.

Neuroophthalmology 2018 Jun 14;42(3):187-190. Epub 2017 Sep 14.

Baylor College of Medicine, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/01658107.2017.1372488DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5958962PMC
June 2018

Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series.

Ann Rheum Dis 2017 Dec 22;76(12):2061-2064. Epub 2017 Aug 22.

Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2017-21156
Publisher Site
http://dx.doi.org/10.1136/annrheumdis-2017-211560DOI Listing
December 2017

Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer.

Arthritis Rheumatol 2017 04 3;69(4):687-699. Epub 2017 Mar 3.

The University of Texas MD Anderson Cancer Center, Houston.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/art.40043DOI Listing
April 2017

Diverse types of dermatologic toxicities from immune checkpoint blockade therapy.

J Cutan Pathol 2017 Feb 21;44(2):158-176. Epub 2016 Dec 21.

Department of Pathology, Section of Dermatopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cup.12858DOI Listing
February 2017

Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features.

Am J Dermatopathol 2017 Feb;39(2):121-129

*Department of Pathology, Section of Dermatopathology, The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of †Dermatology, and ‡Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/DAD.0000000000000688DOI Listing
February 2017

Managing Adverse Events With Immune Checkpoint Agents.

Cancer J 2016 Mar-Apr;22(2):121-9

From the Departments of *Endocrine Neoplasia and Hormonal Disorders and †Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/PPO.0000000000000186DOI Listing
January 2017

Enhanced responses to tumor immunization following total body irradiation are time-dependent.

PLoS One 2013 12;8(12):e82496. Epub 2013 Dec 12.

Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America ; Weill Cornell Medical College, New York, New York, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0082496PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3861406PMC
October 2014